Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes

Diabetes Care

Volumn 24, Issue 10, 2001, Pages 1706-1710

  Moran, Antoinette ^a   Phillips, James ^a   Milla, Carlos ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CARBAMIC ACID DERIVATIVE; DRUG DERIVATIVE; INSULIN; INSULIN LISPRO; PIPERIDINE DERIVATIVE; REPAGLINIDE;

ADULT; ARTICLE; BLOOD; COMPARATIVE STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; FEMALE; FOOD; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MALE; METABOLISM;

ADULT; BLOOD GLUCOSE; CARBAMATES; CYSTIC FIBROSIS; DIABETES MELLITUS; FEMALE; FOOD; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PIPERIDINES;

EID: 0035490420     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.24.10.1706     Document Type: Article

References (23)

1. Moran A, Doherty L, Wang X, Thomas W: Abnormal glucose metabolism in cystic fibrosis. J Pediatr 133:10-16,1998
2. Moran A, Diem P, Klein DJ, Levitt MD, Robertson RP: Pancreatic endocrine function in cystic fibrosis. J Pediatr 118:715-723, 1991
3. Couce M, O'Brien TD, Moran A, Roche PC, Butler PC: Diabetes mellitus in CF is characterized by islet amyloidosis. J Gin Endocrinol Metab 81:1267-1272, 1996
4. Finkelstein SM, Wielinski CL, Elliott GR, Warwick WJ, Barbosa J, Wu SC, Klein DJ: Diabetes mellitus associated with cystic fibrosis. J Pediatr 112:373-377, 1988
5. Cystic Fibrosis Foundation: Patient Registry: Annual Data Report. Bethesda, MD, Cystic Fibrosis Foundation, 1998
6. Lanng S, Thorsteinsson B, Nerup J, Koch C: Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 151:684687, 1992
7. Lanng S, Thorsteinsson B, Nerup J, Koch C: Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr 83:849853, 1994
8. Milla CE, Warwick WJ, Moran A: Trends in pulmonary function in cystic fibrosis patients correlate with the degree of glu-cose intolerance at baseline. Am J Resp Crit Care Med 162:891-895, 2000
9. Steinkamp G, von der Hardt H: Improvement of nutritional status and lung function after long-term nocturnal gastrostomy feedings in cystic fibrosis. J Pediatr 124:244-249, 1994
10. Shepherd RW, Holt TL, Thomas BJ, Kay L, Isles A, Francis PJ, Ward LC: Nutritional rehabilitation in cystic fibrosis: controlled studies of effects on nutritional growth retardation, body protein turnover, and course of pulmonary disease. J Pediatr 109:788-794, 1986
11. Hardin DS, Leblanc A, Lukenbaugh S, Para L, Seilheimer DK: Proteolysis associated with insulin resistance in cystic fibrosis. Pediatrics 101:433-437, 1998
12. Moran A, Milla C, DuCret R, Nair KS: Protein metabolism in clinically stable adult CF patients with abnormal glucose tolerance. Diabetes 50:1336-1343, 2001
13. Moran A, Hardin D, Rodman D, Allen HF, Beall RJ, Borowitz D, Brunzell C, Campbell PW, Chesrown SE, Duchow C, Fink RJ, FitzSimmons SC, Hamilton N, Hirsch I, Howenstine MS, Klein DJ, Madhun Z, Pencharz PB, Quittner AL, Robbins MK, Schindler T, Schissel K, Schwarzenberg SJ, Stallings VA, Tullis E, Zipf WB: Diagnosis, screening, and management of CFRD: a consensus conference report. Diabetes Res Clin Pract 45:55-71, 1999
14. Moran A: CFRD: an approach to diagnosis and management. Pediatr Diabetes 1:1418, 2000
15. Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AAR, Berger M: Prandial glycaemia after a carbohydrate-rich meal in type 1 diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med 13:625-629, 1996
16. Torlone E, Pampanelli S, Lalli C, Del Sin-daco P, Di Vincenzo A, Rambotti AM, Modarelli C, Epifano L, Kassi G, Perreillo G, Brunetti P, Bolli G: Effects of the shortacting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 19:945-952, 1996
17. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR: Lys(B28), Pro(29)-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 43:396-402, 1994
18. Bertele-Harms RM, Harms HK: Sulfonylurea in the treatment of CFRD: a 15 year experience (Abstract). Pediatr Pulmonol 13:380A, 1996
19. Culler FL, McKean LP, Buchanan CJ, Caplan DB, Meacham LR: Glipizide treatment of patients with CF and impaired glucose tolerance. In Endocrine Society Program and Abstracts, San Antonio, TX, 1992. San Antonio, TX, Endocrine Society, 1992, p. 45A
20. Hinds A, Sheehan AG, Parsons HG: Tobutamide causes a modest increase in insulin secretion in CF patients with impaired glucose tolerance. Metabolism 44: 13-18, 1995
21. Horswill CA, Zipf WB, Kien CL, McCoy KS, O'Dorisio TM: Glipizide increased insulin secretion but not growth of children with CF (Abstract). FASEB J 4:3272A, 1990
22. Zipf WB, Kien CL, Horswill CA, McCoy KS, O'Dorisio T, Pinyerd BL: Effects of tolbutamide on growth and body composition of nondiabetic children with CF. Pediatr Res 30:309-314, 1991
23. Sheppard DJ, Welsh MJ: Effect of ATP-sensitive K4+ channel regulators on cystic fibrosis transmembrane conductance regulator chloride currents. J Gen Physiol 100: 573-591, 1992